Genetic predisposition to early recurrence in clinically localized prostate cancer

BJU International

Volumn 111, Issue 4, 2013, Pages 549-558

  Borque, Ángel ^a   Del Amo, Jokin ^c   Esteban, Luis M ^b   Ars, Elisabet ^e   Hernández, Carlos ^g   Planas, Jacques ^f   Arruza, Antonio ^h   Llarena, Roberto ^d   Palou, Joan ^e   Herranz, Felipe ^g   Raventõs, Carles X ^f   Tejedor, Diego ^c   Artieda, Marta ^c   Simon, Laureano ^c   Martínez, Antonio ^c   Carceller, Elena ^a   Suárez, Miguel ^a   Allué, Marta ^f   Sanz, Gerardo ^b   Morote, Juan ^f  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c Progenika Biopharma SA ^*  (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e FUNDACIÓ PUIGVERT   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h Hospital of Txagorritxu Vitoria   (Spain)

Author keywords

genetics; nomograms; progression free survival; prostate cancer; single nucleotide polymorphisms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BGLAP GENE; CALIBRATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; KLK2 GENE; KLK3 GENE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SULT1A1 GENE; TUMOR GENE;

AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SPAIN; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TIME FACTORS;

EID: 84875850928     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11333.x     Document Type: Article

References (44)

1. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute. 2011. Available at: http://seer.cancer.gov/CSR/1975-2008/. Accessed January 2012. Based on November 2010 SEER data submission, posted to the SEER web site, 2011
2. Boorjian SA, Houston Thompson R, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-899
3. Scattoni V, Montorsi F, Picchio M, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int 2004; 93: 680-688
4. Swindle PW, Kattan MW, Scardino PT,. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30: 377-401
5. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
6. Nam RK, Zhang WW, Klotz LH, et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 2006; 12: 6452-6458
7. Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010; 16: 2819-2832
8. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-321
9. Tejedor D, Castillo S, Mozas P, et al. Reliable low density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137-1144
10. Morote J, Del Amo J, Borque A, et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol 2010; 184: 506-511
11. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for standardized definition. J Clin Oncol 2006; 24: 3973-3978
12. Carayol J, Tores F, König IR, Hager J, Ziegler A,. Evaluating diagnostic accuracy of genetic profiles in affected offspring families. Stat Med 2010 29: 2359-2368
13. DeLong ER, DeLong DM, Clarke-Pearson DL., Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics 1988; 44: 837-845
14. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172
15. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006 26: 565-574
16. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
17. Pencina MJ, D'Agostino RB Sr, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21
18. Kattan M,. Comparing prediction tools. Eur Urol 2010; 57: 569-570
19. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974
20. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-1942
21. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-717
22. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597
23. Simmons MN, Stephenson AJ, Klein EA,. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-1184
24. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439
25. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW,. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006; 176: 1404-1408
26. Walz J, Chun FK-H, Klein EA, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009; 181: 601-607
27. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479
28. Mitchell RE, Chang SS,. Current controversies in the treatment of high-risk prostate cancer. Curr Opin Urol 2008; 18: 263-268
29. Kattan MW, Eastham JA, Stapleton AM, Wheeler PM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771
30. Lughezzani G, Briganti A, Karakiewicz P, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010; 58: 687-700
31. Donovan MJ, Khan FM, Fernandez G, et al. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 2009; 182: 125-132
32. Lughezzani G, Budäus L, Isbarn H, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010; 57: 562-568
33. Parikh H, Deng Z, Yeager M, et al. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33. Hum Genet 2010; 127: 91-99
34. Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM,. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008 17: 2451-2457
35. Kader AK, Sun J, Isaacs SD, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009; 69: 1195-1205
36. Witte JS,. Prostate cancer genomics: towards a new understanding. Nat Rev Genet 2009; 10: 77-82
37. Nowell S, Ratnasinghe DL, Ambrosone CB, et al. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2004 13: 270-276
38. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM,. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997; 239: 298-304
39. Wu HC, Lin CC, Chen WC, Chen HI, Tasai FJ,. Osteocalcin gene HindIII C/T polymorphism is a biomarker for prostate cancer and responsiveness to hormone therapy. Eur Urol 2003; 43: 197-200
40. Gardner TA, Lee SJ, Lee SD, et al. Differential expression of osteocalcin during the metastatic progression of prostate cancer. Oncol Rep 2009; 21: 903-908
41. Raldow A, Hamstra DA, Kim SN, Yu JB,. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev 2011; 37: 89-96
42. Zubek VB, Konski A,. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. Mol Diagn Ther 2009; 13: 31-47
43. Quill E,. Medicine. Blood-matching goes genetic. Science 2008; 319: 1478-1479
44. Naito S, Kuroiwa K, Kinukawa N, et al. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol 2008; 180: 904-909